<DOC>
	<DOCNO>NCT01661790</DOCNO>
	<brief_summary>To determine efficacy Safety intrapleural Bevacizumab cisplatin treatment malignant pleural effusion ( MPE ) patient non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Intrapleural Bevacizumab Cisplatin Therapy Malignant Pleural Effusion Caused Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Pleural Effusion , Malignant</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients advance recurrent progressive NSCLC proven cytohistologically Karnofsky performance status ( KPS ) ≥60 Life expectancy ≥ 2 month No history severe diseases major organ include liver , heart , kidney No previous intrapleural therapy Written inform consent Active thoracic cavity systemic bleeding Active pleural systemic infection . Known sensitivity Bevacizumab Cisplatin Refusal participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Bevacizumab ;</keyword>
	<keyword>non-small cell lung cancer ;</keyword>
	<keyword>malignant pleural effusion ;</keyword>
	<keyword>intrapleural administration</keyword>
</DOC>